RxDoctor Payments Data

Frederick de la Vega, MD

Neurology · la Jolla, CANPI 1427169069

Payments from drug & device makers

$6,392in general payments, 2019–2025

Across 269 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$1K
  • AbbVie$707
  • EMD Serono, Inc.$434
  • Amgen$346
  • Acadia Pharmaceuticals Inc$321
  • Amneal Pharmaceuticals LLC$321
  • plus $3K from 31 others

What the payments were for

  • Food & beverage$6,363100%
  • Education$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,392 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$152,406
Medicare patients
248
Services billed
3,944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ApokynApomorphine Hcl15$983,141
NuplazidPimavanserin Tartrate31$244,295
RytaryCarbidopa/Levodopa81$65,238
Glatiramer Acetate14$17,616
Lacosamide36$12,504
Nurtec OdtRimegepant Sulfate11$10,592
Aimovig AutoinjectorErenumab-Aooe11$7,847
Rasagiline Mesylate45$6,641
Carbidopa-LevodopaCarbidopa/Levodopa178$5,081
Quetiapine Fumarate38$3,679
Rivastigmine23$2,716
Donepezil Hcl141$1,887
Memantine Hcl52$1,840
Gabapentin80$1,698
AmantadineAmantadine Hcl28$1,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$321$244,29531 claims
Amneal Pharmaceuticals LLCRytary$321$65,23881 claims
PfizerNurtec Odt$305$10,59211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,996 neurology providers in California.

Other neurology in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →